|
Jul 22
|
Sanofi to Buy Vaccine Developer Vicebio for Up to $1.6 Billion
|
|
Jul 22
|
Replimune drug rejected by FDA; Omega raises $647M biotech fund
|
|
Jul 22
|
Buy Now or Regret Later: This Small-Cap Stock Has Big Disruption Potential
|
|
Jul 22
|
J&J seeks FDA approval for icotrokinra to treat psoriasis
|
|
Jul 22
|
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
|
|
Jul 22
|
Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights
|
|
Jul 22
|
NYC Council's Firewall Starts in District 5--with a Bombshell Named Alina
|
|
Jul 22
|
Is Kenvue (KVUE) a Halal Dividend Stock Worth Adding to Your Portfolio?
|
|
Jul 21
|
Johnson & Johnson (JNJ)’s Pasritamig Shows Breakthrough Promise in Prostate Cancer
|
|
Jul 21
|
AstraZeneca announces $50 billion US manufacturing investment, matching its big pharma peers
|
|
Jul 21
|
Looking for Cheap Stocks? Healthcare Shares Haven’t Looked This Good in 30 Years.
|
|
Jul 21
|
Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?
|
|
Jul 21
|
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
|
|
Jul 21
|
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
|
|
Jul 21
|
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
|
|
Jul 21
|
Ophthalmic Implants Market: Focused Insights (2025-2030) Featuring Alcon, Carl Zeiss, Bausch + Lomb, Johnson & Johnson and 20 Other Industry Leaders
|
|
Jul 21
|
Johnson & Johnson (JNJ): I Counted 15 Separate Surprises,” Says Jim Cramer
|
|
Jul 21
|
Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer
|
|
Jul 21
|
Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis
|
|
Jul 21
|
Johnson & Johnson seeks first icotrokinra U.S. FDA approval aiming to revolutionize treatment paradigm for adults and adolescents with plaque psoriasis
|